Products do matter in pharma, expert tells investors

04/24/2012 | Forbes

Investors considering pharmaceutical makers often do not pay attention to product news because they are too focused on short-term profits, ISI Group biotech and pharma analyst Mark Schoenebaum wrote to his clients. "Over the long term, making money in any biotech or drug stock is about products," he wrote. The fact that the pharma market is slow to respond to product news creates an opportunity for investors, he added.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Senior Manager, Compliance
Stryker
Fremont, CA
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA